View:
Download DOC
Download PDF
Download XLS
tm2314644-13_s4a - block - 2.9687805s
​
As filed with the U.S. Securities and Exchange Commission on July 11, 2023.
Registration No. 333-269138​
​
​
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
​
Amendment No. 6
to
Form S-4
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
​
MEDTECH ACQUISITION CORPORATION
(Exact name of registrant as specified in its charter)
​
​
Delaware
​ ​
6770
​ ​
85-3009869
​
​
(State or other jurisdiction of
incorporation or organization)
​ ​
(Primary Standard Industrial
Classification Code Number)
​ ​
(I.R.S. Employer
Identification Number)
​
48 Maple Avenue
Greenwich, CT 06830
Telephone: (908) 391-1288
(Address, including zip code, and telephone number, including area code,
of registrant’s principal executive offices)
Christopher C. Dewey
Chief Executive Officer
48 Maple Avenue
Greenwich, CT 06830
(908) 391-1288
(Name, address, including zip code, and telephone number, including area code, of agent for service)
​
Copies to:
​
Kevin M. Shuler, Esq.
Paul D. Broude, Esq.
Carolyn T. Long, Esq.
Foley & Lardner LLP
100 North Tampa Street, Suite 2700
Tampa, Florida 33602
(813) 229-2300
​ ​
Matthew Browne, Esq.
Rupa Briggs, Esq.
Alexander Gefter, Esq.
Cooley LLP
10265 Science Center Dr.
San Diego, California 92121
(858) 550-6000
​
Approximate date of commencement of proposed sale of the securities to the public: As soon as practicable after the effective date of this registration statement and the satisfaction or waiver of all other conditions under the Merger Agreement described herein.
If the securities being registered on this Form are being offered in connection with the formation of a holding company and there is compliance with General Instruction G, check the following box: ☐
If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering: ☐
If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering: ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
​ Large accelerated filer ​ ​ ☐ ​ ​ Accelerated filer ​ ​ ☐ ​
​ Non-accelerated filer ​ ​ ☒ ​ ​ Smaller reporting company ​ ​ ☒ ​
​ ​ ​ ​ ​ ​ ​ Emerging growth company ​ ​ ☒ ​
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
If applicable, place an X in the box to designate the appropriate rule provision relied upon in conducting this transaction:
Exchange Act Rule 13e-4(i) (Cross-Border Issuer Tender Offer) ☐
Exchange Act Rule 14d-1(d) (Cross-Border Third-Party Tender Offer) ☐
​
The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.
​
​
​
 
EXPLANATORY NOTE
MedTech Acquisition Corporation is filing this Amendment No. 6 to its registration statement on Form S-4 (File No. 333-269138) (the “Registration Statement”) as an exhibits-only filing. Accordingly, this amendment consists only of the facing page, this explanatory note, Item 21 of Part II of the Registration Statement, the signature page to the Registration Statement and the filed exhibits. The remainder of the Registration Statement is unchanged and has therefore been omitted.
 
​
 
PART II
INFORMATION NOT REQUIRED IN THE PROSPECTUS
Item 21.   Exhibits and Financial Statements Schedules
​ ​ ​ ​ ​ ​ ​
Incorporated by Reference
​
​
Exhibit
​ ​
Description
​ ​
Schedule/​
Form
​ ​
File Number
​ ​
Exhibits
​ ​
Filing Date
​
​ 2.1# ​ ​ Agreement and Plan of Merger, dated as of November 11, 2022, by and among MedTech Acquisition Corporation, MTAC Merger Sub, Inc., and TriSalus Life Sciences, Inc. (included as Annex A-1 to this proxy statement/prospectus). ​ ​
Form 8-K
​ ​
001-39813
​ ​
2.1
​ ​
November 14, 2022
​
​ 2.2 ​ ​ First Amendment to Agreement and Plan of Merger, dated as of April 4, 2023, by and among MedTech Acquisition Corporation, MTAC Merger Sub, Inc., and TriSalus Life Sciences, Inc. (included as Annex A-2 to this proxy statement/​prospectus). ​ ​
Form 8-K
​ ​
001-39813
​ ​
10.1
​ ​
April 5, 2023
​
​ 2.3 ​ ​ Second Amendment to Agreement and Plan of Merger, dated as of May 13, 2023, by and among MedTech Acquisition Corporation, MTAC Merger Sub, Inc., and TriSalus Life Sciences, Inc. (included as Annex A-3 to this proxy statement/​prospectus). ​ ​
Form 8-K
​ ​
001-39813
​ ​
10.1
​ ​
May 13, 2023
​
​ 2.4 ​ ​ Third Amendment to Agreement and Plan of Merger, dated as of July 5, 2023, by and among MedTech Acquisition Corporation, MTAC Merger Sub, Inc., and TriSalus Life Sciences, Inc. (included as Annex A-4 to this proxy statement/​prospectus). ​ ​
Form 8-K
​ ​
001-39813
​ ​
10.1
​ ​
July 6, 2023
​
​ 3.1 ​ ​ Amended and Restated Certificate of Incorporation of MTAC. ​ ​
Form 8-K
​ ​
001-39813
​ ​
3.1
​ ​
December 23, 2020
​
​ 3.2 ​ ​ Bylaws of MTAC. ​ ​
Form S-1
​ ​
333-251037
​ ​
3.3
​ ​
November 30, 2020
​
​ 3.3 ​ ​ Second Amended and Restated Certificate of Incorporation of Combined Company (included as Annex B to this proxy statement/prospectus). ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
 
II-1
​
 
​ ​ ​ ​ ​ ​ ​
Incorporated by Reference
​
​
Exhibit
​ ​
Description
​ ​
Schedule/​
Form
​ ​
File Number
​ ​
Exhibits
​ ​
Filing Date
​
​ 3.4 ​ ​ Amended and Restated Bylaws of Combined Company (included as Annex C to this proxy statement/prospectus). ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​ 3.5 ​ ​ ​ ​
Form 8-K
​ ​
001-39813
​ ​
3.1
​ ​
December 19, 2022
​
​ 3.6 ​ ​ Form of Certificate of Designations, Preferences and Rights of Series A Convertible Preferred Stock of TriSalus Life Sciences, Inc. (included as Annex G to this proxy statement/​prospectus). ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​ 3.7 ​ ​ ​ ​
Form 8-K
​ ​
001-39813
​ ​
3.1
​ ​
June 15, 2023
​
​ 4.1 ​ ​ ​ ​
Form S-1/A
​ ​
333-251037
​ ​
4.1
​ ​
December 9, 2020
​
​ 4.2 ​ ​ ​ ​
Form S-1/A
​ ​
333-251037
​ ​
4.2
​ ​
December 9, 2020
​
​ 4.3 ​ ​ ​ ​
Form S-1/A
​ ​
333-251037
​ ​
4.3
​ ​
December 9, 2020
​
​ 4.4 ​ ​ ​ ​
Form 8-K
​ ​
001-39813
​ ​
4.1
​ ​
December 23, 2020
​
​ 5.1 ​ ​ ​ ​
Form S-4/A
​ ​
333-269138
​ ​
5.1
​ ​
July 6, 2023
​
​ 10.1 ​ ​ ​ ​
Form 8-K
​ ​
001-39813
​ ​
10.1
​ ​
November 14, 2022
​
​ 10.2 ​ ​ ​ ​
Form 8-K
​ ​
001-39813
​ ​
10.2
​ ​
November 14, 2022
​
 
II-2
​
 
​ ​ ​ ​ ​ ​ ​
Incorporated by Reference
​
​
Exhibit
​ ​
Description
​ ​
Schedule/​
Form
​ ​
File Number
​ ​
Exhibits
​ ​
Filing Date
​
​ 10.3# ​ ​ ​ ​
Form 8-K
​ ​
001-39813
​ ​
10.3
​ ​
November 14, 2022
​
​ 10.4 ​ ​ ​ ​
Form 8-K
​ ​
001-39813
​ ​
10.4
​ ​
November 14, 2022
​
​ 10.5 ​ ​ ​ ​
Form 8-K
​ ​
001-39813
​ ​
10.5
​ ​
November 14, 2022
​
​ 10.6 ​ ​ ​ ​
Form 8-K
​ ​
001-39813
​ ​
10.6
​ ​
November 14, 2022
​
​ 10.7* ​ ​ TriSalus Life Sciences, Inc. 2023 Equity Incentive Plan (included as Annex D to this proxy statement/prospectus). ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​ 10.8* ​ ​ TriSalus Life Sciences, Inc. 2023 Employee Stock Purchase Plan (included as Annex E to this proxy statement/prospectus). ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​ 10.9 ​ ​ ​ ​
Form 8-K
​ ​
001-39813
​ ​
10.1
​ ​
December 23, 2020
​
​ 10.10 ​ ​ ​ ​
Form 8-K
​ ​
001-39813
​ ​
10.2
​ ​
December 23, 2020
​
​ 10.11 ​ ​ ​ ​
Form 8-K
​ ​
001-39813
​ ​
10.1
​ ​
December 19, 2022
​
 
II-3
​
 
​ ​ ​ ​ ​ ​ ​
Incorporated by Reference
​
​
Exhibit
​ ​
Description
​ ​
Schedule/​
Form
​ ​
File Number
​ ​
Exhibits
​ ​
Filing Date
​
​ 10.12 ​ ​ ​ ​
Form 8-K
​ ​
001-39813
​ ​
10.2
​ ​
December 19, 2022
​
​ 10.13## ​ ​ ​ ​
Form S-4/A
​ ​
333-269138
​ ​
10.13
​ ​
April 21, 2023
​
​ 10.14*## ​ ​ ​ ​
Form S-4/A
​ ​
333-269138
​ ​
10.14
​ ​
April 21, 2023
​
​ 10.15*## ​ ​ ​ ​
Form S-4/A
​ ​
333-269138
​ ​
10.15
​ ​
April 21, 2023
​
​ 10.16*## ​ ​ ​ ​
Form S-4/A
​ ​
333-269138
​ ​
10.16
​ ​
April 21, 2023
​
​ 10.17*## ​ ​ ​ ​
Form S-4/A
​ ​
333-269138
​ ​
10.17
​ ​
April 21, 2023
​
​ 10.18*## ​ ​ ​ ​
Form S-4/A
​ ​
333-269138
​ ​
10.18
​ ​
April 21, 2023
​
​ 10.19*## ​ ​ ​ ​
Form S-4/A
​ ​
333-269138
​ ​
10.19
​ ​
April 21, 2023
​
​ 10.20## ​ ​ Strategic Collaboration Agreement, dated March 2, 2021, by and between Surefire Medical Inc. d/b/a TriSalus Life Sciences and The University of Texas M.D. Anderson Cancer Center. ​ ​
Form S-4/A
​ ​
333-269138
​ ​
10.20
​ ​
April 21, 2023
​
 
II-4
​
 
​ ​ ​ ​ ​ ​ ​
Incorporated by Reference
​
​
Exhibit
​ ​
Description
​ ​
Schedule/​
Form
​ ​
File Number
​ ​
Exhibits
​ ​
Filing Date
​
​ 10.21 ​ ​ ​ ​
Form 8-K
​ ​
001-39813
​ ​
10.1
​ ​
March 8, 2023
​
​ 10.22 ​ ​ ​ ​
Form 8-K
​ ​
001-39813
​ ​
10.1
​ ​
June 8, 2023
​
​ 10.23 ​ ​ ​ ​
Form 8-K
​ ​
001-39813
​ ​
10.2
​ ​
June 8, 2023
​
​ 10.24## ​ ​ ​ ​
Form S-4/A
​ ​
333-269138
​ ​
10.24
​ ​
June 8, 2023
​
​ 10.25# ​ ​ ​ ​
Form S-4/A
​ ​
333-269138
​ ​
10.25
​ ​
July 6, 2023
​
​ 10.26 ​ ​ ​ ​
Form 8-K
​ ​
001-39813
​ ​
10.1
​ ​
June 15, 2023
​
​ 10.27# ​ ​ ​ ​
Form S-4/A
​ ​
333-269138
​ ​
10.27
​ ​
July 6, 2023
​
​ 10.28 ​ ​ Amendment No. 1 to Engagement Letter Agreement, dated June 7, 2023, by and among MedTech Acquisition Corporation, MedTech Acquisition Sponsor LLC, and Ceros Financial Services, Inc. ​ ​
Form S-4/A
​ ​
333-269138
​ ​
10.28
​ ​
July 6, 2023
​
​ 10.29 ​ ​ ​ ​
Form 8-K
​ ​
001-39813
​ ​
10.2
​ ​
July 6, 2023
​
 
II-5
​
 
​ ​ ​ ​ ​ ​ ​
Incorporated by Reference
​
​
Exhibit
​ ​
Description
​ ​
Schedule/​
Form
​ ​
File Number
​ ​
Exhibits
​ ​
Filing Date
​
​ 10.30 ​ ​ ​ ​
Form 8-K
​ ​
001-39813
​ ​
10.3
​ ​
July 6, 2023
​
​ 21.1 ​ ​ ​ ​
Form S-4
​ ​
333-269138
​ ​
21.1
​ ​
January 6, 2023
​
​ 23.1 ​ ​ ​ ​
Form S-4/A
​ ​
333-269138
​ ​
23.1
​ ​
July 6, 2023
​
​ 23.2 ​ ​ ​ ​
Form S-4/A
​ ​
333-269138
​ ​
23.2
​ ​
July 6, 2023
​
​ 23.3 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​ 24.1 ​ ​ ​ ​
Form S-4
​ ​
333-269138
​ ​
24.1
​ ​
January 6, 2023
​
​ 99.1 ​ ​ ​ ​
Form S-4
​ ​
333-269138
​ ​
99.1
​ ​
January 6, 2023
​
​ 99.2 ​ ​ ​ ​
Form S-4
​ ​
333-269138
​ ​
99.2
​ ​
January 6, 2023
​
​ 99.3 ​ ​ ​ ​
Form S-4
​ ​
333-269138
​ ​
99.3
​ ​
January 6, 2023
​
​ 99.4 ​ ​ ​ ​
Form S-4/A
​ ​
333-269138
​ ​
99.4
​ ​
May 23, 2023
​
​ 99.5 ​ ​ ​ ​
Form S-4/A
​ ​
333-269138
​ ​
99.5
​ ​
May 23, 2023
​
​ 99.6 ​ ​ ​ ​
Form S-4/A
​ ​
333-269138
​ ​
99.6
​ ​
May 23, 2023
​
​ 99.7 ​ ​ ​ ​
Form S-4/A
​ ​
333-269138
​ ​
99.7
​ ​
May 23, 2023
​
​ 99.8 ​ ​ ​ ​
Form S-4/A
​ ​
333-269138
​ ​
99.8
​ ​
May 23, 2023
​
​ 99.9 ​ ​ ​ ​
Form S-4/A
​ ​
333-269138
​ ​
99.9
​ ​
May 23, 2023
​
​ 99.10 ​ ​ ​ ​
Form S-4/A
​ ​
333-269138
​ ​
99.10
​ ​
July 6, 2023
​
​ 101.INS ​ ​ Inline XBRL Instance Document. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​ 101.CAL ​ ​ Inline XBRL Taxonomy Extension Calculation Linkbase Document. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​ 101.SCH ​ ​ Inline XBRL Taxonomy Extension Schema Document. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
 
II-6
​
 
​ ​ ​ ​ ​ ​ ​
Incorporated by Reference
​
​
Exhibit
​ ​
Description
​ ​
Schedule/​
Form
​ ​
File Number
​ ​
Exhibits
​ ​
Filing Date
​
​ 101.DEF ​ ​ Inline XBRL Taxonomy Extension Definition Linkbase Document. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​ 101.LAB ​ ​ Inline XBRL Taxonomy Extension Labels Linkbase Document. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​ 101.PRE ​ ​ Inline XBRL Taxonomy Extension Presentation Linkbase Document. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​ 104 ​ ​ Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​ 107 ​ ​ ​ ​
Form S-4/A
​ ​
333-269138
​ ​
107
​ ​
May 23, 2023
​
​
*
Indicates management contract or compensatory plan or arrangement.
​
#
Certain of the exhibits and schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5). The Registrant agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request; provided, however, that MTAC may request confidential treatment pursuant to Rule 24b-2 of the Exchange Act, as amended, for any schedule or exhibit so furnished.
​
##
Certain portions of this Exhibit have been omitted in accordance with Regulation S-K Item 601(b)(10)(iv) because they are not material and are the type of information that the Registrant treats as private or confidential. The Registrant agrees to furnish supplementally an unredacted copy of the Exhibit, or any section thereof, to the SEC upon request.
​
 
II-7
​
 
SIGNATURES
Pursuant to the requirements of the Securities Act, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, on the 11th day of July, 2023.
MedTech Acquisition Corporation
By:
/s/ Christopher C. Dewey
​
​
Name:
Christopher C. Dewey
​
Title:
Chief Executive Officer
​
Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.
​
Signature
​ ​
Title
​ ​
Date
​
​
/s/ Christopher C. Dewey
​
Christopher C. Dewey
​ ​ Chief Executive Officer and Director ​ ​
July 11, 2023
​
​
/s/ David J. Matlin
​
David J. Matlin
​ ​ Chief Financial Officer and Director ​ ​
July 11, 2023
​
​
/s/ *
​
Karim Karti
​ ​ Chairman ​ ​
July 11, 2023
​
​
/s/ *
​
Martin Roche, MD
​ ​ Director ​ ​
July 11, 2023
​
​
/s/ *
​
Thierry Thaure
​ ​ Director ​ ​
July 11, 2023
​
​
/s/ *
​
Manuel Aguero
​ ​ Director ​ ​
July 11, 2023
​
​
/s/ *
​
David L. Treadwell
​ ​ Director ​ ​
July 11, 2023
​
​
*By
/s/ Christopher C. Dewey
​
​
Christopher C. Dewey
Attorney-in-fact
 
II-8